More on ASND
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $215.60 |
|
|||
| Open | $216.50 | ||||
| 52 Wk High | $21.79 | ||||
| 52 Wk Low | $11.92 | ||||
| Day High | $224.11 | ||||
| Day Low | $216.50 | ||||
| P/E | N/A | ||||
| EPS | $-0.07 | ||||
| Volume | 307,931 | ||||
- Form 6-K Ascendis Pharma A/S For: Jun 12
- Ascendis reports 5-year TransCon PTH data in hypoparathyroidism patients
- 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
- Form 6-K Ascendis Pharma A/S For: Jun 10
- Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND)
- Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
- Analysts see a buying opportunity in this pharma stock
- Form 4 Ascendis Pharma A/S For: Jun 02 Filed by: SMITH SCOTT THOMAS
- Form 4 Ascendis Pharma A/S For: May 29 Filed by: BIENAIME JEAN JACQUES
- Form 4 Ascendis Pharma A/S For: May 29 Filed by: SMITH SCOTT THOMAS
Entities mentioned with ASND
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
